Alimta Indications/Uses

Malignant pleural mesothelioma: ALIMTA in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.
Non-small cell lung cancer: ALIMTA in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see Pharmacology: Pharmacodynamics under Actions).
ALIMTA is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see Pharmacology: Pharmacodynamics under Actions).
ALIMTA is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see Pharmacology: Pharmacodynamics under Actions).
ALIMTA in combination with pembrolizumab and platinum chemotherapy, is indicated for the first line treatment of patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumor aberrations.